Somerset Emsam NDA Resubmission Adds Long-Term Indication, Higher Doses
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Somerset’s resubmitted NDA for the selegiline patch Emsam seeks an indication for relapse prevention as well as treatment of depression.
You may also be interested in...
Valeant Responds To Zelapar Approvable Letter, Plans For Mid-2005 Launch
Valeant responds to Zelapar “approvable” letter for Parkinson’s disease; “complete response” includes two safety studies, as requested in FDA’s 2003 approvable letter for the MAO-B inhibitor. Selegiline safety concerns include drug interactions, hypertension due to “cheese effect”
Valeant Responds To Zelapar Approvable Letter, Plans For Mid-2005 Launch
Valeant responds to Zelapar “approvable” letter for Parkinson’s disease; “complete response” includes two safety studies, as requested in FDA’s 2003 approvable letter for the MAO-B inhibitor. Selegiline safety concerns include drug interactions, hypertension due to “cheese effect”
Somerset Emsam "approvable
Somerset receives "approvable" letter Jan. 30 for its transdermal selegiline patch, Emsam. The Mylan/Watson joint venture indicated that FDA is requesting additional pharmacology/toxicology studies as well as postmarketing pharmacokinetic and safety studies. Tyramine dietary restrictions in labeling are also requested. The sponsors resubmitted the Emsam NDA Aug. 1, 2003 for treatment of depression following a March 2002 "not approvable" letter (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 14)...